Treatment of Cogan's Syndrome in Children and Adolescents (Age Under 18)

Cogan's syndrome is a rare inflammatory condition primarily affecting the eyes and auditory system. Its occurrence in pediatric patients is exceptionally uncommon — only around fifty cases have been described in the literature.

Clinical scenario: Pediatric patient under 18 years of age presenting with Cogan's syndrome. The very low prevalence in this age group makes agent selection particularly consequential, with tolerability in children a key consideration.

Treatment approach (partial overview): Management involves immunosuppressant therapy, with agent choice in this age group guided by the tolerability profile specific to children. The complete structured protocol — including preferred agents, sequencing, and monitoring parameters — is available below.

Instant Access to Structured Evidence-Based Regimens

References

Cogan's syndrome is a complex condition primarily affecting the auditory system and the eyes and has been very rarely described in children, with around fifty reported cases.

Treatment relies on steroid therapy and immunosuppressants, with a preference for mycophenolate mofetil or azathioprine over cyclophosphamide in case of systemic involvement due to their tolerability profile.

DOI: 10.1016/j.revmed.2024.09.007

View source ↗